Approval · Notice of Compliance 11209 · 2010
MYLAN-DIVALPROEX: Notice of Compliance 11209
Issued March 31, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11209
- Date
- March 31, 2010
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Therapeutic class
- Anticonvulsant
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYLAN-DIVALPROEX | Not yet assigned | — |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB